Cycle Pharmaceuticals receives license for IP on PARP inhibitor drugs for treating vascular disease

The University of Cambridge and King's College London have jointly developed intellectual property (IP) regarding the underlying cellular mechanisms that cause the calcification (or hardening) of arteries and veins as we age. These biological processes can cause vascular diseases and, through impeding blood flow, can cause heart disease and stroke. The recently licenced IP includes a patent application and know-how relating to the use of PARP inhibitor drugs for the treatment of vascular disease. This IP has been licensed by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to CYCLE Pharmaceuticals.